Espinosa O, Drummond M, Russo E, Williams D, Wix D
Int J Technol Assess Health Care. 2025; 41(1):e3.
PMID: 39757736
PMC: 11703631.
DOI: 10.1017/S0266462324004781.
Levaggi L, Levaggi R
Pharmacy (Basel). 2024; 12(2).
PMID: 38525730
PMC: 10961771.
DOI: 10.3390/pharmacy12020050.
Eckermann S
Front Public Health. 2024; 12:1212439.
PMID: 38510345
PMC: 10951103.
DOI: 10.3389/fpubh.2024.1212439.
Paulden M
Pharmacoeconomics. 2023; 42(2):145-164.
PMID: 38066357
PMC: 10810971.
DOI: 10.1007/s40273-023-01325-z.
Toubes-Navarro M, Gude-Sampedro F, Alvarez-Dobano J, Reyes-Santias F, Rabade-Castedo C, Rodriguez-Garcia C
Ann Thorac Med. 2023; 18(4):190-198.
PMID: 38058789
PMC: 10697305.
DOI: 10.4103/atm.atm_70_23.
Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
Rane A, Nechi R, Imam M, Zoni C, Ndikumukiza C, Karaye I
J Manag Care Spec Pharm. 2023; 29(9):1045-1053.
PMID: 37610112
PMC: 10508839.
DOI: 10.18553/jmcp.2023.29.9.1045.
Estimation of Value-Based Price for 48 High-Technology Medical Devices.
Hyeraci G, Trippoli S, Rivano M, Messori A
Cureus. 2023; 15(6):e39934.
PMID: 37287820
PMC: 10243399.
DOI: 10.7759/cureus.39934.
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?.
Bussgen M, Stargardt T
Appl Health Econ Health Policy. 2023; 21(5):751-759.
PMID: 37249741
PMC: 10227403.
DOI: 10.1007/s40258-023-00815-7.
What are the impacts of increasing cost-effectiveness Threshold? a protocol on an empirical study based on economic evaluations conducted in Thailand.
Isaranuwatchai W, Nakamura R, Wee H, Sarajan M, Wang Y, Soboon B
PLoS One. 2022; 17(10):e0274944.
PMID: 36191016
PMC: 9529087.
DOI: 10.1371/journal.pone.0274944.
How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations.
Sandmann F, Ramsay M, Edmunds W, Choi Y, Jit M
Value Health. 2021; 24(10):1391-1399.
PMID: 34593161
PMC: 9525135.
DOI: 10.1016/j.jval.2021.03.022.
The economics of alternative payment models for pharmaceuticals.
Hlavka J, Yu J, Goldman D, Lakdawalla D
Eur J Health Econ. 2021; 22(4):559-569.
PMID: 33725260
PMC: 8169601.
DOI: 10.1007/s10198-021-01274-4.
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
Vreman R, Broekhoff T, Leufkens H, Mantel-Teeuwisse A, Goettsch W
Int J Environ Res Public Health. 2020; 17(22).
PMID: 33182732
PMC: 7698033.
DOI: 10.3390/ijerph17228309.
Mesenchymal stem cells in neurodegenerative diseases: Opinion review on ethical dilemmas.
Scopetti M, Santurro A, Gatto V, La Russa R, Manetti F, DErrico S
World J Stem Cells. 2020; 12(3):168-177.
PMID: 32266049
PMC: 7118285.
DOI: 10.4252/wjsc.v12.i3.168.
Examining the Use of Real-World Evidence in the Regulatory Process.
Beaulieu-Jones B, Finlayson S, Yuan W, Altman R, Kohane I, Prasad V
Clin Pharmacol Ther. 2019; 107(4):843-852.
PMID: 31562770
PMC: 7093234.
DOI: 10.1002/cpt.1658.
The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice.
Peng Y, Lee C, Tain Y, Huang Y, Chuang H, Wen Y
PLoS One. 2019; 14(8):e0221504.
PMID: 31449565
PMC: 6709886.
DOI: 10.1371/journal.pone.0221504.
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective.
van Asten F, Michels C, Hoyng C, van der Wilt G, Klevering B, Rovers M
PLoS One. 2018; 13(5):e0197670.
PMID: 29772018
PMC: 5957378.
DOI: 10.1371/journal.pone.0197670.
Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
Maniadakis N, Kourlaba G, Shen J, Holtorf A
BMC Health Serv Res. 2017; 17(1):371.
PMID: 28545440
PMC: 5445358.
DOI: 10.1186/s12913-017-2304-2.
The (Ir)relevance of Group Size in Health Care Priority Setting: A Reply to Juth.
Sandman L, Gustavsson E
Health Care Anal. 2016; 25(1):21-33.
PMID: 27734213
PMC: 5313590.
DOI: 10.1007/s10728-016-0333-3.
Sustainable Financing of Innovative Therapies: A Review of Approaches.
Hollis A
Pharmacoeconomics. 2016; 34(10):971-80.
PMID: 27251182
DOI: 10.1007/s40273-016-0416-x.
Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.
Messori A
Clin Drug Investig. 2016; 36(8):599-603.
PMID: 27216427
DOI: 10.1007/s40261-016-0408-9.
